The trial of UroLift System, a device being developed by a Pleasanton, California based NeoTract, Inc., has now been initiated in the US, according to the company. The minimally invasive technology is designed to treat lower urinary symptoms of benign prostatic hyperplasia (BPH) by opening the urinary pathway by retracting hyperplastic urethral tissue “without applying incisions, surgical resection or thermal injury to the prostate.”
From the product page:
1. The UroLift delivery device is inserted transurethrally through a rigid sheath (not shown) under cystoscopic visualization to reach the targeted area of obstruction.
2. UroLift sutures are deployed through a needle that comes out of the delivery device to retract the obstructing lobes.
3. The UroLift delivery device and sheath are removed, leaving an expanded urethral lumen.
UroLift System Treatment Highlights:
•Endoscopic results can be immediately confirmed post-procedure.
•The procedure may be performed under local anesthesia.
•Some patients can avoid any catheterization
•Patients may experience symptom relief as early as 2 weeks post-procedure.
•There have been no reports of new onset of sexual dysfunction, retrograde ejaculation or permanent erectile dysfunction.
• UroLift system treatment does not preclude the option for future TURP should one be indicated
Press release: NeoTract Announces First U.S. Patients Enrolled in Study of New Minimally Invasive Device for Benign Prostatic Hyperplasia …
Product page: UroLift System …